SELECT-MDS-1

• Research type

  Research Study

• Full title

  A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome

• IRAS ID

  1004001

• Contact name

  Ashley Preston

• Contact email

  apreston@syros.com

• Sponsor organisation

  Syros Pharmaceuticals, Inc

• Eudract number

  2020-004528-40

• Clinicaltrials.gov Identifier

  NCT04797780

• Research summary

  A study to test how the investigational drug SY-1425 (tamibarotene) works in combination with azacitidine to treat higher-risk Myelodysplastic Syndrome (MDS) in patients with a certain biomarker in their blood.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  21/LO/0607

• Date of REC Opinion

  11 Oct 2021

• REC opinion

  Unfavourable Opinion